Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Leading a Comprehensive Cancer Center—one job or two?
- Rathmell: To improve funding outlook, we must reverse distrust in science
- My bad: I left out Fox Chase